LPCN:NSC-Lipocine Inc.

EQUITY | Drug Manufacturers | NASDAQ Capital Market

Last Closing Price

USD 1.43

Change

-0.04 (-2.72)%

Market Cap

USD 0.03B

Volume

0.54M

Yahoo Analyst Target

USD 12.00 (739.16%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Lipocine Inc is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc.

+0.22 (+0.29%)

USD 75.29B
MYL Mylan N.V.

-0.27 (-0.58%)

USD 24.95B
NBIX Neurocrine Biosciences Inc.

+2.68 (+3.53%)

USD 6.95B
HCM Hutchison China MediTech Limit..

+0.25 (+0.63%)

USD 5.28B
AKRX Akorn Inc.

-0.09 (-0.27%)

USD 4.13B
GWPH GW Pharmaceuticals Plc

-0.45 (-0.34%)

USD 3.35B
HZNP Horizon Pharma plc

+0.22 (+1.47%)

USD 2.49B
IRWD Ironwood Pharmaceuticals Inc.

+0.10 (+0.67%)

USD 2.25B
SUPN Supernus Pharmaceuticals Inc.

-2.95 (-6.34%)

USD 2.23B
AERI Aerie Pharmaceuticals Inc.

+0.50 (+0.87%)

USD 2.13B

ETFs Containing LPCN

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.43% 3% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.43% 3% F N/A N/A
Trailing 12 Months  
Capital Gain -57.82% 13% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.82% 13% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.33% 47% F 43% F
Dividend Return 5.33% 47% F 39% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 60.26% 37% F 16% F
Risk Adjusted Return 8.85% 47% F 29% F
Market Capitalization 0.07B 15% F 12% F

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -1.51 31% F 63% D
Price/Book Ratio 1.20 81% B- 77% C+
Price / Cash Flow Ratio -0.43 39% F 72% C-
Price/Free Cash Flow Ratio -1.91 38% F 63% D
Management Effectiveness  
Return on Equity -74.61% 41% F 14% F
Return on Invested Capital -75.46% 36% F 12% F
Return on Assets -68.40% 20% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.